ストックスクリーナーアプリを入手
3.86
1.85%
0.07
アフターアワーズ：
3.81
-0.05
-1.30%
Rocket Pharmaceuticals Inc (RCKT) 最新ニュース
RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off - Stocktwits
RCKT News | ROCKET PHARMACEUTICALS INC (NASDAQ:RCKT) - ChartMill
Rocket Pharmaceuticals Inc. (RCKT) Key Financial Ratios – Valuation, Profitability & More - Value Research
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
Rocket Pharma (NASDAQ: RCKT) to pull 2026 warrant listing - Stock Titan
Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating - Investing.com
Chardan assumes Rocket Pharmaceuticals stock coverage with buy rating By Investing.com - Investing.com Canada
New Jersey's Rocket Pharma Strikes New Pay Deal For Its GC - Law360
Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - GuruFocus
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock By Investing.com - Investing.com South Africa
Rocket Pharmaceuticals CEO Gaurav Shah sells $7,752 in shares By Investing.com - Investing.com Nigeria
Rocket Pharmaceuticals CEO Gaurav Shah sells $7,752 in shares - Investing.com
Rocket Pharmaceuticals general counsel Martin Wilson sells $2,133 in stock - Investing.com
Rocket (RCKT) EPS and Revenue: EPS Falls Short of Its Estimate on the Day; After Results: Shares Finish 1.76% Down in the Latest SessionEarnings Outlook Update - vinanet.vn
Rocket Pharma (NASDAQ: RCKT) sale tied to 2026 vesting, tax bill - Stock Titan
Rocket Pharma (NASDAQ: RCKT) officer to resell $2.1K in vested shares - Stock Titan
Rocket Pharma (NASDAQ: RCKT) ex-officer to unload equity-award shares - Stock Titan
Rocket Pharmaceuticals general counsel Wilson sells $11,809 in stock - Investing.com
Rocket Pharmaceuticals CEO Gaurav Shah sells $9,591 in company stock - Investing.com
Rocket Pharmaceuticals CEO Gaurav Shah sells $9,591 in company stock By Investing.com - Investing.com Canada
Rocket Pharmaceuticals general counsel Wilson sells $11,809 in stock By Investing.com - Investing.com Canada
RCKT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Rocket Pharmaceuticals' General Counsel Martin Wilson Sells Shares to Cover RSU Tax Obligations - Kalkine Media
Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells $11,806.34 in Stock - MarketBeat
Monaco Asset Management SAM Invests $8.48 Million in Rocket Pharmaceuticals, Inc. $RCKT - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Don't Ignore The Insider Selling In Rocket Pharmaceuticals - simplywall.st
Rocket Pharmaceuticals Inc (RCKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rocket Pharmaceuticals Executive Sells Shares to Cover RSU Tax Withholding - Kalkine Media
Rocket Pharmaceuticals (NASDAQ:RCKT) COO Christopher James Stevens Sells 36,658 Shares of Stock - MarketBeat
Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Sells $16,453.50 in Stock - MarketBeat
Rocket Pharmaceuticals (RCKT) COO sells 36,658 shares to cover RSU tax withholding - Stock Titan
RCKT (RCKT) insider Martin Wilson plans sale of 3,493 vested shares - Stock Titan
Gaurav Shah plans stock sale in RCKT (RCKT) after prior share disposals - Stock Titan
Rocket Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CCORF Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Rocket Pharmaceuticals (RCKT) - The Globe and Mail
Morgan Stanley Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating, Maintains Target Price $5 - Moomoo
ROCKET PHARMACEUTICALS, INC. SEC Filing (Aug 11, 2026) - Stock Titan
TD Cowen Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating - Moomoo
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus - Yahoo Finance
Rocket Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $8.84, Implies 143% Upside - TradingView
RCKT Maintains Rating by Wedbush -- Price Target Lowered to $15 - GuruFocus
Wedbush Issues Pessimistic Forecast for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price - MarketBeat
Rocket Pharmaceuticals, Inc. expected to post a loss of 42 cents a shareEarnings Preview - TradingView
Rocket Pharmaceuticals Q2 adj EPS $(0.37) misses $0.24 estimate - scanx.trade
ROCKET PHARMACEUTICALS, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $7 FROM $12 - Bitget
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress - AOL.com
ROCKET PHARMACEUTICALS ($RCKT) Releases Q2 2026 Earnings - Quiver Quantitative
Rocket Pharmaceuticals: Q2 Earnings Snapshot - barchart.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Quarterly Earnings Results, Beats Estimates By $0.22 EPS - MarketBeat
BRIEF-Rocket Pharmaceuticals Q2 EPS USD 1.08 - Bitget
Rocket Pharmaceuticals reports Q2 2026 net income $123.2M, cash $283.7M, eyes Danon pivotal progress - tradingview.com
Rocket Pharmaceuticals (RCKT) Tops Q2 EPS by 6c; offers guidance - streetinsider.com
ROCKET PHARMACEUTICALS, INC. Q2 2026: Revenue $0 Net income $123.2M, EPS $1.08— 10-Q Summary - tradingview.com
Rocket Pharmaceuticals posts Q2 profit helped by PRV sale - TradingView
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):